gemcitabine/nab-paclitaxel

Phase 2Small molecule

gemcitabine/nab-paclitaxel is one of 109 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic AdenocarcinomaActive, not recruiting

MelanomaCompleted

Pancreatic CancerActive, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

MelanomaPhase 1

Completed

Pancreatic CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

108 2

gemcitabine/nab-paclitaxel

Eli Lilly

Phase 2

5 3

MS Contin

Merck & Co.

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Byetta

AstraZeneca

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

ABI-007

Bristol-Myers Squibb

Preclinical

2 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Thiazolidinediones

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Efficacy

NCT06922591

Clinical

Trials by Indication[1]

Pancreatic Cancer5 trials

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Unknown status·SSilenseed Ltd·Phase 2·NCT01676259·80 enrolled

Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer

Completed·—·N/A·NCT02318095·40 enrolled

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Terminated·NNathan Bahary, MD·Phase 2·NCT02241551·2 enrolled

Show 2 more trials

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Terminated·MMassachusetts General Hospital·Phase 2·NCT02243007·7 enrolled

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Withdrawn·SSorrento Therapeutics, Inc.·Phase 2/3·NCT04037241

Efficacy1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting·TTango Therapeutics, Inc.·Phase 1/2·NCT06922591·183 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Completed·PPureTech·Phase 1/2·NCT04666688·44 enrolled

Pancreatic Adenocarcinoma1 trial

Pancreatic Adenocarcinoma Signature Stratification for Treatment

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04469556·150 enrolled

Melanoma1 trial

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02009449·353 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for gemcitabine/nab-paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine/nab-paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine/nab-paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

gemcitabine/nab-paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pancreatic Cancer5 trials

Efficacy1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Pancreatic Adenocarcinoma1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News